Literature DB >> 18310287

BRAF(V600E) mutation and the biology of papillary thyroid cancer.

F Frasca1, C Nucera, G Pellegriti, P Gangemi, M Attard, M Stella, M Loda, V Vella, C Giordano, F Trimarchi, E Mazzon, A Belfiore, R Vigneri.   

Abstract

BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers. We evaluated the relationship between BRAF((V600E)) and tumor, host, and environmental factors in PTCs from all geographical areas of Sicily. By PCR, BRAF((V600E)) was investigated in a series of 323 PTCs diagnosed in 2002-2005. The correlation between clinicopathological tumor, host, and environmental characteristics and the presence of BRAF((V600E)) were evaluated by both univariate and multivariate analyses. BRAF((V600E)) was found in 38.6% PTCs, with a 52% frequency in the classical PTCs and 26.4% in the tall cell variant. Univariate analysis indicated that BRAF((V600E)) was associated with greater tumor size (P=0.0048), extra-thyroid invasion (P<0.0001), and cervical lymph nodal metastases (P=0.0001). Multivariate logistic regression analysis confirmed that BRAF((V600E)) was an independent predictor of extra-thyroid invasion (P=0.0001) and cervical lymph nodal metastasis (P=0.0005). The association between BRAF((V600E)) and extra-thyroid invasion was also found in micro-PTCs (P=0.006). In 60 classical PTCs, BRAF((V600E)) was positively correlated with matrix metalloproteinase-9 expression (P=0.0047), suggesting a possible mechanism for BRAF((V600E)) effect on PTC invasiveness. No association was found between BRAF((V600E)) and patient age, gender, or iodine intake. In contrast, a strong association was found with residency in Eastern Sicily (P<0.0001 compared with Western Sicily). These results indicate that BRAF((V600E)) mutation is a marker of aggressive disease in both micro- and macro-PTCs. Moreover, for the first time, a possible link between BRAF((V600E)) mutation and environmental carcinogens is suggested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310287     DOI: 10.1677/ERC-07-0212

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  92 in total

1.  Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo.

Authors:  D Chan; J W Tyner; W J Chng; C Bi; R Okamoto; J Said; B D Ngan; G D Braunstein; H P Koeffler
Journal:  Oncol Lett       Date:  2012-01-20       Impact factor: 2.967

2.  DARPP-32 is required for MAPK/ERK signaling in thyroid cells.

Authors:  Ana Chocarro-Calvo; Miguel A Zaballos; Pilar Santisteban; Custodia García-Jiménez
Journal:  Mol Endocrinol       Date:  2012-02-02

3.  The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes.

Authors:  C Regalbuto; P Malandrino; F Frasca; G Pellegriti; R Le Moli; R Vigneri; V Pezzino
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

4.  A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma.

Authors:  Leo A Niemeier; Haruko Kuffner Akatsu; Chi Song; Sally E Carty; Steven P Hodak; Linwah Yip; Robert L Ferris; George C Tseng; Raja R Seethala; Shane O Lebeau; Michael T Stang; Christopher Coyne; Jonas T Johnson; Andrew F Stewart; Yuri E Nikiforov
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

Review 5.  The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?

Authors:  Carmelo Nucera; Jack Lawler; Richard Hodin; Sareh Parangi
Journal:  Oncotarget       Date:  2010-12

6.  BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI).

Authors:  Hong Xie; Bojun Wei; Hong Shen; Ying Gao; Lingling Wang; Hui Liu
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

7.  BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Authors:  Neslihan Kurtulmus; Mete Duren; Umit Ince; M Cengiz Yakicier; Onder Peker; Ozlem Aydın; Ender Altiok; Serdar Giray; Halil Azizlerli
Journal:  Endocrine       Date:  2012-03-17       Impact factor: 3.633

8.  Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?

Authors:  Kathleen C Lee; Carol Li; Eric B Schneider; Yongchun Wang; Helina Somervell; Matthew Krafft; Christopher B Umbricht; Martha A Zeiger
Journal:  Surgery       Date:  2012-10-11       Impact factor: 3.982

Review 9.  Prognostic utility of BRAF mutation in papillary thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

Review 10.  Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

Authors:  Carmelo Nucera; Melanie Goldfarb; Richard Hodin; Sareh Parangi
Journal:  Biochim Biophys Acta       Date:  2009-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.